NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 130 filers reported holding NURIX THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,506 | +115.8% | 72,154 | +51.9% | 0.00% | – |
| Q1 2024 | $698 | -1.6% | 47,515 | -30.9% | 0.00% | – |
| Q4 2023 | $709 | +33.8% | 68,739 | +1.9% | 0.00% | – |
| Q3 2023 | $530 | -23.2% | 67,467 | -2.2% | 0.00% | – |
| Q2 2023 | $690 | +7.5% | 68,991 | -4.4% | 0.00% | – |
| Q1 2023 | $642 | -41.3% | 72,147 | -27.6% | 0.00% | – |
| Q4 2022 | $1,094 | -99.9% | 99,657 | +17.9% | 0.00% | -100.0% |
| Q3 2022 | $1,101,000 | +3138.2% | 84,491 | +2993.8% | 0.00% | – |
| Q2 2022 | $34,000 | -52.8% | 2,731 | -47.3% | 0.00% | – |
| Q1 2022 | $72,000 | – | 5,179 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP III, LLC | 3,422,549 | $90,800,000 | 15.85% |
| Ponoi II Management, LLC | 686,274 | $18,207,000 | 14.76% |
| Ponoi Management, LLC | 686,274 | $18,207,000 | 10.12% |
| Foresite Capital Management V, LLC | 451,522 | $11,979,000 | 4.71% |
| Foresite Capital Management IV, LLC | 1,205,798 | $31,990,000 | 4.32% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $34,073,000 | 2.23% |
| EcoR1 Capital, LLC | 1,967,950 | $52,210,000 | 1.95% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $15,155,000 | 1.93% |
| DAFNA Capital Management LLC | 306,320 | $8,127,000 | 1.70% |
| Euclidean Capital LLC | 154,426 | $4,097,000 | 1.33% |